Elotuzumab with Lenalidomide, Dexamethasone Beneficial in Multiple Myeloma

May 13, 2015 9:16 PM

14 0

Elotuzumab with Lenalidomide, Dexamethasone Beneficial in Multiple Myeloma

Patients with relapsed/refractory multiple myeloma who received elotuzumab in addition to lenalidomide and dexamethasone had a longer duration of remission and higher overall response rate without a significant increase in adverse events, a study presented in an American Society of Clinical Oncology (ASCO) presscast ahead of the 2015 ASCO Annual Meeting has shown.

The phase 3 ELOQUENT-2 study, enrolled 646 patients with relapsed or refractory multiple myeloma who had received between one and three prior treatments for their disease. Participants were randomly assigned to receive lenalidomide 25 mg orally plus dexamethasone with or without elotuzumab 10 mg/kg ...

Read more

To category page

Loading...